ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Expression and diagnostic significance of plasma exosomal RNA in diffuse large B-cell lymphoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to investigate the expression profiles of plasma exosomal RNAs in patients with Diffuse Large B-Cell Lymphoma (DLBCL) and evaluate their diagnostic potential.
methodsExosomes were isolated from 9 DLBCL patients and 9 healthy controls, followed by whole transcriptome RNA sequencing to identify differentially expressed RNAs. Key RNAs were selected and validated via qRT-PCR using an independent cohort of 41 treatment-naïve DLBCL patients and 41 healthy controls. The StarBase database was utilized to predict target relationships and construct lncRNA/miRNA competing endogenous RNA (ceRNA) pairs. Diagnostic efficacy was assessed using Receiver Operating Characteristic (ROC) curve analysis.
resultsHigh-throughput sequencing revealed significant RNA expression differences between DLBCL patients and healthy controls. Specifically, 35 microRNAs (miRNAs), 1604 long non-coding RNAs (lncRNAs), and 330 messenger RNAs (mRNAs) were differentially expressed in the DLBCL group, while no significant differences were observed in circular RNA (circRNA) expression. Two ceRNA pairs, MALAT1/hsa-miR-181a-5p and SLC9A3-AS1/hsa-miR-10a-5p, were constructed. qRT-PCR validation confirmed that hsa-miR-181a-5p and hsa-miR-10a-5p were significantly down-regulated, while SLC9A3-AS1 was up-regulated in the DLBCL group; MALAT1 expression showed no significant difference. ROC analysis demonstrated Area Under the Curve (AUC) values of 0.813 for hsa-miR-181a-5p, 0.800 for hsa-miR-10a-5p, and 0.787 for SLC9A3-AS1. The combined AUC for SLC9A3-AS1 and hsa-miR-10a-5p was 0.8226, and for SLC9A3-AS1 and hsa-miR-181a-5p was 0.852.
conclusionExosome-derived miRNAs, lncRNAs, and mRNAs exhibit distinct expression patterns in DLBCL patients compared to healthy controls. The RNAs hsa-miR-181a-5p, hsa-miR-10a-5p, and SLC9A3-AS1 show promise as diagnostic biomarkers for DLBCL, with combined RNA panels offering improved diagnostic efficacy over single markers. The SLC9A3-AS1/hsa-miR-10a-5p pair may form a regulatory network influencing DLBCL pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.